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http:WHAT THIS PAPER ADDS
This national survey found that the invasive treatment incidence of infrainguinal intermittent claudication (IC)
was 8.9 per 100,000 inhabitants in Sweden in 2009 despite current guidelines recommending no treatment for
infrainguinal lesions in patients with IC in most cases. A systematic review of the 12-month follow-up results
from the 775 patients (843 procedures) is presented. The identiﬁed results of satisfactory outcome in three out
of four patients warrants further studies of whether or not invasive treatment of infrainguinal IC is appropriate.Objectives: In spite of recommendations advocating conservative best medical treatment, many patients with
infrainguinal intermittent claudication (IC) are treated by invasive open and endovascular methods. This study
aims to evaluate the incidence and 1-year results of all such treatments during 2009 in Sweden.
Methods: The design was a one-year follow-up through the Swedish Vascular Registry (Swedvasc) of all 775
patients from the Swedish population of 10 million inhabitants in whom 843 invasive infrainguinal procedures
(796 index procedures and 47 secondary procedures) were performed for IC in 2009. Index procedures were
open surgery in 290 (37%) patients, bilateral in nine cases, giving a total of 299 limbs, endovascular treatment in
447 (58%) patients, bilateral in 10, giving a total of 457 limbs, and hybrid treatment in 38 (5%) patients, bilateral
in two cases, giving a total of 40 limbs. Data were analysed both with regard to the number of patients (775) and
the number of procedures (843). Clinical outcome was calculated from patient-reported leg function (unchanged,
improved, deteriorated) and whether amputation had been necessary or death had occurred. Patent
reconstruction at 1 year was also counted as improvement.
Results: Improvement at 1 year was seen in 567 (73.2%) patients, (225 [77.6%] in the open surgery group, 320
[71.6%] in the endovascular treatment group, and 22 [57.9%] in the hybrid treatment group). No signiﬁcant
difference was found between the open surgery and endovascular treatment groups comprising 737/775
patients (p ¼ .350). Hybrid treatment gave signiﬁcantly worse results (p ¼ .046). Fifty-seven (7.3%) patients
reported unchanged limb function and 32 (4.1%) patients reported deterioration. Within 30 days two patients
died and one patient underwent amputation.Within 1 year 10 patients underwent 11 amputations: ﬁve (1.7%) in
the open surgery group, three (0.6%) in the endovascular treatment group, and two (7.5%) in the hybrid
treatment group; one underwent bilateral amputation (p ¼ .07). Twenty-two patients died: 10 (3.4%) in the open
surgery group, 12 (2.7%) in the endovascular treatment group and none in the hybrid treatment group
(p ¼ .465).
Conclusions: Reported improvement at 1 year was 73.2% in patients invasively treated for infrainguinal IC.
Patients reporting an unchanged or deteriorated clinical state are a considerable clinical challenge. Further
studies to determine whether or not invasive treatment of infrainguinal IC is appropriate are justiﬁed.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Peripheral arterial disease (PAD) is a common atheroscle-
rotic manifestation occurring in 18% of subjects 60e90
years of age.1 The prevalence of the different stages of PAD,
asymptomatic PAD, intermittent claudication (IC), and
Table 1. Deﬁnition of risk factors in Swedvasc 2.0.
Hypertension Treatment with antihypertensive drug
Diabetes mellitus Pharmacological treatment of
diabetes mellitus
Cardiac risk Previous myocardial infarction,
current angina pectoris, previous
heart surgery or endovascular cardiac
intervention
Renal risk Serum creatinine above 150 mmol/L or
preoperative haemo- or peritoneal dialysis
Cerebral event Previous cerebrovascular lesion with
residual symptoms and/or radiologically
veriﬁed brain injury
Current smoking Ongoing smoking or smoking cessation
within last 5 years
Table 2. Detailed description of 796 index procedures, i.e. limbs,
and level of landing zone, n (%). in all 775 Swedish patients
undergoing invasive infrainguinal treatment of intermittent
claudication in 2009.
Above knee
653 (82)
Below
knee 143 (18)
Thromboendarterectomy 128 (16.1) 0 (0)
Bypass (graft) 58 (7.3) 6 (0.8)
Bypass (vein) 35 (4.4) 38 (4.8)
Exploration 15 (1.9) 3 (0.4)
Other open 11 (1.4) 3 (0.4)
Percutaneous angioplasty 187 (23.5) 54 (6.8)
Subintimal recanalization 76 (9.5) 12 (1.5)
Stent implantation 100 (12.6) 24 (3.0)
Other endovascular
treatment
1 (0.1) 0 (0)
Thrombectomy 2 (0.2) 0 (0)
Thrombolysis 2 (0.2) 1 (0.1)
Hybrid procedure 38 (4.8) 2 (0.2)
616 H. Lindgren et al.critical limb ischaemia (CLI) vary with age, gender, and
geographic region.1 The prevalence of IC in Sweden has
been reported to be 6.5% in women and 7.2% in men aged
60e90 years.1
The management of IC traditionally consists of risk factor
modiﬁcation and conservative best medical treatment with
or without supervised exercise training.2
The role of invasive treatment such as open surgery or
endovascular treatment remains controversial in this con-
dition, especially when IC is caused by infrainguinal disease.
In general, the restriction of patient quality of life by IC has
not been considered great enough to justify the risks of
open surgery.3
Whereas the results of inﬂow procedures such as re-
constructions above the inguinal ligament in patients with
IC are good with 91% primary patency at 6 years,4 the
treatment of infrainguinal lesions remains a challenge to
both open surgery and endovascular treatment. Bypass
surgery is associated with complications (such as wound
infection) and prolonged hospital stay.5 One main problem
with endovascular infrainguinal treatment is restenosis.
Follow-up studies have established that restenosis rates
are dependent upon both the length of the stented
segment, the number of stents placed, and the stent
brand used.6
The best treatment for IC should provide the best quality
of life for the patient as well as the best survival and limb
salvage rate.2,7 Both international2 and Swedish7 guidelines
recommend that infrainguinal lesions should not be revas-
cularized in most patients with IC. In spite of this, according
to the Swedish Vascular Registry (Swedvasc)8 843 of a total
of 3,304 invasive infrainguinal procedures (open and
endovascular) performed in Sweden in 2009 for PAD, were
undertaken on patients with IC. Endovascular treatment
was performed in 60% of these.
The aim of this study was to evaluate the one year results
of these 843 procedures in Swedish patients treated for
infrainguinal IC by invasive methods during 2009.
MATERIALS AND METHODS
Population
We conducted a follow-up study, using the Swedvasc reg-
istry,8 of all 843 prospectively registered infrainguinal
treatments performed on 775 patients for IC in Sweden in
2009. The procedures were analysed in three groups: open
surgery, endovascular treatment, and hybrid treatment
(deﬁned as registration of open surgery and endovascular
treatment of two or more infrainguinal lesions at same
date). The Swedvasc registry has an external validity of 93%
of infrainguinal procedures.9 In Swedvasc, data on preop-
erative risk factors (Table 1) for patients undergoing
vascular treatment at Swedish hospitals are registered
together with the type of treatment (open surgery, endo-
vascular treatment, or hybrid treatment) and patients are
followed up at 1 and 12 months.8
Follow-up data at 1 year regarding improvement,
deterioration, amputation, death, complications,occlusion, reoperation, cerebrovascular and cardiovascular
events were analysed both with regard to the number of
patients (775) and the number of procedures (843; 796
index procedures, i.e. limbs, and 47 secondary pro-
cedures). The secondary procedures (23 ipsilateral rein-
terventions and 24 new interventions on the other side)
contribute to the clinical outcome evaluated 1 year after
the index procedure.
The index procedures were open surgery in 290 (37%)
patients, bilateral in nine cases, giving a total of 299 limbs,
endovascular treatment in 447 (58%) patients, bilateral in
10 cases, giving a total of 457 limbs, and hybrid treatment
in 38 (5%) patients, bilateral in two cases, giving a total of
40 limbs. The type of procedures and their distal landing
zones are described in detail in Table 2. Clinical outcome
was evaluated in a composite variable from patient-
reported leg function (unchanged, improved, deteriorated)
and whether amputation had been necessary or death had
occurred. Patent reconstruction at 1 year was also counted
as improvement. Ankleebrachial index (ABI) values were
not entered into the composite outcome variable list
because of inconsistency in their registration: only 82% at
baseline and 62% at 12 months.10
Figure 1. Flow chart of 843 invasive infrainguinal procedures
performed in all 775 Swedish patients undergoing invasive
infrainguinal treatment of intermittent claudication in 2009.
Table 3. Background variables, n (%), in all 775 Swedish patients
undergoing invasive infrainguinal treatment of intermittent
claudication in 2009.
Open Endovascular Hybrid p
Gender 0.885
Female 110 (37.9) 179 (40.0) 15 (39.5)
Male 180 (61.9) 268 (59.9) 23 (60.5)
Age (SD) 69.6 (10.6) 71.8 (8.8) 69.8 (9.0) 0.007
Hypertension 218 (74.9) 344 (76.8) 29 (76.3) 0.843
Diabetes
mellitus
55 (18.9) 116 (25.9) 10 (26.3) 0.081
Cardiac risk 93 (32.0) 156 (34.8) 17 (44.7) 0.273
Renal risk 13 (4.5) 20 (4.5) 2 (5.3) 0.974
Cerebral event 21 (7.2) 50 (11.2) 5 (13.2) 0.163
Current
smoking
123 (42.3) 149 (33.3) 18 (47.4) 0.020
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The study was approved by the Ethics Committee at Lund
University (Ref. no. 2010/549).Table 4. Thirty-day complications, n (%) in all 796 index
procedures, i.e. limbs, in all 775 Swedish patients undergoing
invasive infrainguinal treatment of intermittent claudication in
2009.
Open Endovascular Hybrid p
Wound complication 46 (15.3) 7 (1.5) 4 (10) <.0001
Occlusion 8 (2.7) 17 (3.7) 1 (2.5) .703
Reoperation due
to bleeding
5 (1.7) 3 (0.6) 0 (0) .317
Compartment
syndrome
2 (0.7) 1 (0.2) 0 (0) .568
Amputation 0 (0) 1 (0.2) 0 (0) .690
Myocardial
infarction
0 (0) 1 (0.2) 2 (5.3) <.0001
Major stroke 1 (0.3) 1 (0.2) 1 (2.5) .077
Death 1 (0.3) 1 (0.2) 0 (0) .904
Note. Myocardial infarction and major stroke counted on 775
patients.Statistics
Data are reported as mean (SD). The Student t test was used
to evaluate differences in continuous variables and the chi-
square test was used to evaluate differences in nominal
variables between groups. Multiple logistic regression
analysis was performed, with all factors found to differ
between groups in univariate analyses. Calculations were
performed using SPSS 18.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Baseline data
Of a total of 3,304 invasive procedures on patients with
chronic PAD performed in Sweden in 2009 and registered in
the Swedvasc database, 843 were invasive infrainguinal
procedures performed on 775 patients for IC (Fig. 1). This
corresponds to a treatment incidence of 8.9 per 100,000
inhabitants per year. During the preceding 10 years, 236 of
these patients had been registered as undergoing 370
treatments.
Among the patients 304 (39.2%) were women and 471
(60.8%) men. The mean age was 70.4 (SD 9.6) years, 72.6
(SD 8.4) years in women and 69.7 (SD 10.1) years in men.
591 (76.2%) of patients were on antihypertensive treat-
ment, 181 (23.3%) had diabetes mellitus, 266 (34.3%) had
cardiac risk factors, 76 (9.8%) had had a previous cerebro-
vascular event, 35 (4.5%) had renal impairment, and 290
(37.4%) were current smokers or former smokers within the
last 5 years.
The only difference in preoperative risk factor distribu-
tion was that patients undergoing endovascular treatment
(71.8 [SD 8.8] years) were signiﬁcantly older than patients
treated by open surgery (69.6 [SD 10.6] years) and hybrid
treatment (69.8 [SD 9.0] years; p ¼ .007); they more often
had ABI >0.5 (72.7% vs. 61.7% in the open surgery groupand 50.0% in the hybrid treatment group; p ¼ .002), and
were less often current or former smokers within the last 5
years (33.3% vs. 42.3% in the open surgery group and 47.4%
in the hybrid treatment group; p ¼ .020) (Table 3).30-day follow-up data
Within 30 days two patients had died and one patient had
undergone amputation. A total of 101 (12.7%) post-
operative complications were registered: 62 (20.7%) in the
open surgery group, 31 (6.8%) in the endovascular treat-
ment group, and eight (20.0%) in the hybrid treatment
group (p < .0001, Table 4). The most frequently reported
complications at 30 days were wound complications
(n ¼ 57 [7.1%]) and occlusions (n ¼ 26 [3.3%]). One 74-
year-old male treated endovascularly, who had suffered a
compartment syndrome and was treated by fasciotomy, had
continuing IC at 30 days. One 79-year-old male with
occluded ﬁbular and tibial posterior arteries was treated by
percutaneous angioplasty (PTA) of the anterior tibial artery
and had an amputation within 30 days. Seven wound
complications occurred after endovascular procedures, ﬁve
angioplasties and two stent placements in the superﬁcial
Table 5. Clinical outcome in 737 of 775 patients undergoing
invasive infrainguinal treatment of intermittent claudication in
2009.
Open Endovascular Total
Improved 225 (77.6) 320 (71.5) 545 (73.9)
Unchanged 16 (5.5) 37 (8.3) 53 (7.2)
Deteriorated 7 (2.4) 21 (4.9) 28 (3.8)
Living amputated 2 (0.7) 3 (0.7) 5 (0.7)
Dead 8 (2.7) 11 (2.5) 19 (2.6)
Amputated and dead 2 (0.7) 1 (0.2) 3 (0.4)
Missing data 30 (10.3) 54 (12.1) 84 (10.8)
Note. Hybrid procedures were excluded, n (%); p ¼ .350.
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Complications within 30 days were more frequently re-
ported in patients who later underwent amputation than in
non-amputated patients (3.5% vs. 1.0%; p ¼ .02).One-year follow-up data
Clinical outcome in 775 patients. Improvement at 1 year
was reported by 567 (73.2%) patients (225 [77.6%] in the
open surgery group, 320 [71.6%] in the endovascular
treatment group, and 22 [57.9%] in the hybrid treatment
group; p ¼ .046). Fifty-seven (7.3%) patients reported un-
changed limb function, and 32 (4.1%) patients reported
deterioration .When analysing the 737 individuals in the
open surgery and endovascular treatment groups
(comprising 95% of the study population) and excluding the
small hybrid treatment group (with inferior outcome) from
the analysis, there was no signiﬁcant difference between
the groups (Table 5).
The 12-month mortality rate was 22/775 (2.8%): 10
(3.4%) in the open surgery group, 12 (2.7%) in the endo-
vascular treatment group, and none in the hybrid treatment
group (p ¼ .465).
Clinical outcome in 843 procedures. The 843 procedures
consisted of 796 index procedures (i.e. limbs) and 47 sec-
ondary procedures. Improvement at 1 year was reported in
579 (72.7%) limbs (234 [78.2%] in the open surgery group,
322 [70.4%] in the endovascular treatment group, and 23
[57.5%] in the hybrid treatment group; p ¼ .006). Fifty-four
(7.1%) limbs had unchanged function and 30 (4.0%) limbs
had deteriorated function (Table 6). When the small hybrid
treatment group (40 limbs) was excluded from the analysisTable 6. Clinical outcome, n (%), in 756 of 796 index procedures of
invasive infrainguinal treatment of intermittent claudication in
2009.
Open Endovascular Total
Improved 234 (78.2) 322 (70.6) 556 (73.5)
Unchanged 15 (5.0) 39 (8.5) 54 (7.1)
Deteriorated 7 (2.3) 23 (5.0) 30 (4.0)
Living amputated 2 (0.7) 3 (0.7) 5 (0.7)
Dead 8 (2.7) 11 (2.4) 19 (2.5)
Amputated and dead 2 (0.7) 1 (0.2) 3 (0.4)
Missing data 31 (10.3) 58 (12.7) 89 (11.8)
Note. Hybrid procedures were excluded; p ¼ .139.no signiﬁcant difference in functional outcome was seen
between the open surgery and endovascular treatment
groups (p ¼ .139, Table 6).
The 12-month amputation rate was 11/796 (1.4%): ﬁve
(1.7%) in the open surgery group, three (0.6%) in the
endovascular treatment group and three amputations
(7.5%); one patient had bilateral amputation in the hybrid
treatment group (p ¼ .07). Three amputated patients died
within the 12-month follow-up period (Table 6).
New interventions were performed in 47 (5.9%) cases.
Reintervention on the index side was performed in 10
(3.3%) cases in the open surgery group and in 13 (2.8%)
cases in the endovascular treatment group (p ¼ .062). New
contralateral interventions were performed in six (2.0%)
cases in the open surgery group, in 17 (3.7%) cases in the
endovascular treatment group and one (2.5%) case in the
hybrid treatment group (p ¼ .519). The ABI was available at
baseline for 654/796 (82%) procedures and at 12 months
for 496/796 (62%) procedures.
Follow-up data at 1 year was missing in 10.8% of cases,
80% of which were due to a decision by the surgeon at the
30-day visit that the patient did not need further follow-up.
None of these patients was reported as deceased within 1
year to the National Population Registry with virtually 100%
validity, nor were any amputations reported to the obliga-
tory National In-patient Registry for these individuals. Thus
all patients were followed up with respect to amputation
and survival.
Treatments were registered as primary successful in all
cases except 11/91 (12.1%) subintimal angioplasties, 2/41
(4.9%) hybrid procedures, and 3/253 (1.2%) PTAs.
Neither the type of institution (tertiary centre, or county
hospital), nor patient characteristics (age, sex, hypertension,
diabetic mellitus, renal impairment, cardiovascular risk,
cerebrovascular risk, smoking or distal landing zone) inﬂu-
enced the improvement rate after 1 year in multiple
regression analysis (data not shown).DISCUSSION
In this nationwide study of patients undergoing infraingui-
nal invasive treatment of IC, the self-reported improvement
rate 1 year after treatment was 73.2%. The remaining 26.8%
of patients either did not beneﬁt from the treatment or
were lost to follow-up at 1 year. When comparing the re-
sults of the open surgery and endovascular treatment
groups (comprising 95% of the study population) no sig-
niﬁcant difference in clinical outcome was found but hybrid
treatment gave signiﬁcantly worse results.
When assessing PAD treatment, it is important to
recognize that the disease can affect both legs in one in-
dividual. This study comprised 775 patients with 796 index
procedures (limbs), and the results in both limbs must
consequently be taken into account when evaluating the
clinical outcome in patients undergoing bilateral treatment.
In a register study like the present one, the responsible
clinician has chosen a particular treatment for the individual
patient for reasons not entered into the register. As patients
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register is not designed to compare results between treat-
ment groups. However, it may be relevant for use when
searching for underlying risk factors or particular treatment
issues inﬂuencing treatment results within groups. The
present study could not demonstrate such factors in either
uni- or multivariate analysis.
Previous randomized trials comparing different treat-
ments for IC have shown varying results. Spronk et al.11
found no difference in walking performance or health-
related quality of life (HRQL) at 12 months when
comparing hospital-based supervised exercise training with
endovascular intervention. Nordanstig et al.12 reported no
signiﬁcant improvement in maximal walking performance
with invasive treatment (open or endovascular) compared
with non-invasive treatment in a randomized study of un-
selected supra- and infrainguinal IC patients, whereas a
moderate to large positive effect on HRQL (as a secondary
outcome measure) was found in the invasive treatment
group. In the light of new data on the efﬁcacy of supervised
exercise training,13 results from studies of treatment of IC
should be evaluated in the context of the natural history of
IC: about 50% of patients become symptom free and only
1e3% require an amputation during a 5-year follow-up
period.14
When comparing these results with others, it is impor-
tant to note that these data are based on a large unselected
total nationwide record of invasively treated patients with
infrainguinal IC, whereas previously reported clinical tri-
als11,12 have included smaller numbers of patients. It is
reasonable to believe that these results adequately reﬂect
the efﬁcacy of the current clinical practice of invasive
treatment for infrainguinal IC in Sweden.
Furthermore, results of different studies on IC can be
hard to compare due to the different inclusion and
outcome parameters used. While other studies often
involve suprainguinal and infrainguinal cases of IC,11,12 this
study has selectively chosen infrainguinal IC. Which
outcome parameters are relevant when studying IC is also
open to debate. Whereas mortality and limb salvage are
reasonable outcomes to assess after vascular intervention
in CLI patients, there is more controversy regarding which
parameters are relevant after interventions for IC. Older
studies often evaluated maximum walking capacity and
ABI, whereas more recent studies have often included
HRQL questionnaires. As the Swedvasc registry did not
collect information on walking distance or quality of life in
2009, the present study has focused upon the readily
available parameters of self-reported improvement,
amputation, and death.
International data on the incidence of invasive treatment
of infrainguinal IC are sparse and hard to interpret. The
Swedish incidence of 8.9 per 100,000/year can be
compared with data from Vascunet on 32,084 cases of
infrainguinal bypass surgery in nine countries which showed
that the incidence per 100,000 individuals varied between
2.3 and 24.6. Of these, the rate for procedures performed
on IC patients varied from 15.7% to 40.8%.15There are some limitations to this study. Being an
observational study it is dependent on correct data entry
into the register by the many different responsible clini-
cians, which might contribute to the rather high likelihood
of missing data in the study; in fact, 80% of missing data at
12 months was due to a decision taken by the responsible
clinician at the 30-day visit. The Swedvasc register is, how-
ever, well documented with high external validity9 and has
provided background data for many scientiﬁc reports.16e19
The register does not give speciﬁc information about the
lesion anatomy or post-procedure antiplatelet therapy,
factors that might have been valuable in evaluating cases of
deterioration or lack of improvement. The fact that the
small group that underwent hybrid procedures had a worse
outcome might, however, reﬂect the fact that these pa-
tients have more extensive underlying disease with at least
two distinct lesions.
It is important to include factors contributing to subop-
timal results and patient satisfaction. One such factor,
missing in the register, might be the severity of the IC. The
disease might, in some cases, be mild and not restricting
quality of life enough to merit invasive treatment.2 On the
other hand, in other cases it might be so severe that the
need for later amputation rather reﬂects failure to reverse
an already severe ischaemic damage at presentation rather
than the loss of patency of the treated segments.20
The potential inﬂuence of other medical conditions such
as diseases of the spine, hips, or knees and musculoskeletal
pain might all affect walking ability and are common causes
of reduced HRQL.21
The prevalence of IC in Sweden has been reported to be
6.5% in women and 7.2% in men aged 60e90 years.1 As
only invasively treated patients are listed in the Swedvasc
registry and there is no registry on conservative treatment
of IC in Sweden, we cannot provide data on the quality and
efﬁcacy of conservative treatment. This study has clariﬁed,
however, that the incidence of invasive treatment for
infrainguinal IC in Sweden is 8.9/100,000 inhabitants per
year in spite of current recommendations.2,7 The fact that
236 of these 775 patients had been registered as under-
going 370 invasive treatments for infrainguinal IC during the
10 preceding years reﬂects the chronic character of PAD and
the palliative character of its treatment.
The results from this study, with 75% of patients reporting
improvement and 15% reporting no beneﬁt of treatment,
have to be compared with the natural course of the dis-
ease.14 Such a comparison challenges the rationale of
treating infrainguinal IC patients invasively at all, and high-
lights the need for controlled prospective randomized clinical
trials assessing outcomes with special focus on HRQL. One
such study is currently recruiting Swedish patients with IC
with lesions in the SFA, randomizing them to either endo-
vascular stenting or conservative best medical treatment
with 2 year follow-up with regard to quality of life.FUNDING
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